Epigenetics
Continued from page 36
necessary investment to package and deliver new technologies appropriately.
Many companies around the world, including Cambridge Epigenetix, are at the forefront of epi- genetic discovery, particularly concerning the map- ping of 5mC and 5hmC modifications, analysis of LQB samples and identification of new therapeutic targets. These organisations are applying in-house expertise and working collaboratively with com- mercial and academic partners to drive fresh inno- vations that may improve identification and man- agement of disease. Working alongside academic institutions to sup- port development of novel techniques for detection and mapping of epigenetic modifications and biomarker discovery enables commercial organisa- tions to keep abreast of the very latest research and innovations in this area. Knowledge sharing with other experts, for example in the field of LQB, fur- ther supports efficient and rapid biomarker discov- ery. Collaborative approaches with pharmaceutical partners will enable application of these biomark- ers across platforms for companion diagnostics, new therapies and technologies that support per- sonalised medicine.
As our understanding of the epigenome contin- ues to deepen and evolve, the opportunities for innovation and application of this knowledge in the clinical setting are expanding considerably. In the future, these advances may help to shape our long-term approach to the management of human health and well-being; enabling ongoing monitor-
Drug Discovery World Fall 2017
ing of our epigenome and opportunities to imple- ment clinical interventions early in disease devel- opment or adapt our lifestyles appropriately to avoid health issues. It is our vision that, through advancing epigenetic discovery, we will be able to make disease optional, not inevitable.
DDW
Dr Jason Mellad is the Chief Executive Officer at Cambridge Epigenetix. Jason has a BSc in Molecular Biology and Chemistry from Tulane University and was a Marshall Scholar at the University of Cambridge where he completed a PhD in Medicine.
17 Koschmieder et al. Epigenetic dysregulation in chronic myeloid leukaemia: A myriad of mechanisms and therapeutic options. Semin Cancer Biol. 2017 Aug 2. 18 Joosten et al. Prognostic DNA methylation markers for renal cell carcinoma: a systematic review. Epigenomics. 2017;9(9): 1243-1257. 19 Micevic et al. Aberrant DNA methylation in melanoma: biomarker and therapeutic opportunities. Clinical Epigenetics 2017;9:34. 20Tomasetti et al. Circulating epigenetic biomarkers in lung malignancies: From early diagnosis to therapy. Lung Cancer 2017;107:65-72. 21 Giannopoulou et al. Liquid biopsy in ovarian cancer: recent advances on circulating tumor cells and circulating tumor DNA. Clin Chem Lab Med. 2017. 22 Komatsubara et al. Circulating Tumor DNA as a Liquid Biopsy: Current Clinical Applications and Future Directions. Oncology (Williston Park). 2017;31(8):618-27. 23 Heerboth et al. Use of Epigenetic Drugs in Disease: An Overview. Genetics & Epigenetics 2014:6 9–19. 24Yunfeng et al. HEDD: the human epigenetic drug database. Database 2016; 1-10 25 Altucci et al. Epigenetic drugs: from chemistry via biology to medicine and back. Clinical Epigenetics 2016;8:56. 26Yun et al. Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials. Clinical Epigenetics 2016;8:68. 27 de Lera et al. Epigenetic polypharmacology: from combination therapy to s drugs. Clinical Epigenetics (2016) 8:105.
37
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72
